VIDEO: ‘Powerful’ efficacy of JAK inhibitors driving expanded use in IBD
Click Here to Manage Email Alerts
In this Healio video, Edward V. Loftus Jr., MD, previews this month’s Healio Exclusive, in which experts tout the positive attributes of Janus kinase inhibitors for inflammatory bowel disease and discuss their role in the treatment landscape.
“The efficacy of these drugs is so powerful,” Loftus, the Maxine and Jack Zarrow Family Professor of Gastroenterology at the Mayo Clinic and chief medical editor of Healio Gastroenterology, said. “For many doctors it’s analogous to when infliximab came out in 1998. It took a few years for people to get used to that, and then the efficacy overtook concerns about the safety. I think that’s where JAK inhibitors are today.”
In his accompanying editorial in the October issue, Loftus noted that in his experience, JAK inhibitors are well-tolerated and “one only has to see the rapid onset and magnitude of efficacy a few times in patients to understand the power of this class.”
He added, “With time, one’s comfort level with prescribing this class of drugs will increase significantly, resulting in a valuable addition to your toolbox.”
Collapse
Healio Interviews
Click Here to Manage Email Alerts